Cadence Minerals #KDNC – Director Share Purchase and Defined Director Purchase Programme
Cadence Minerals #KDNC announces that the Directors of the Company have acquired 6.7 million shares in the company at an average price of 0.28 pence. In addition, all of the Directors have entered into a Defined Director Purchase Programme. Director Share Purchase Details of the Director purchases are contained in the table below: Date Purchased […]
Advanced Oncotherapy (AVO) – Additional director dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 59.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares […]
Advanced Oncotherapy (AVO) – Additional Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 55 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 723,946 Ordinary […]
Tertiary Minerals (TYM) – Director Dealing, Issue of Equity, Total Voting Rights
Tertiary Minerals plc, the AIM traded company building a strategic position in the fluorspar sector announces that pursuant to terms agreed on 30 April 2014 and further to the RNS dated 20 August 2014, a non-executive director of the Company will be receiving a portion of his annual fees in ordinary shares of 1 pence […]
Tertiary Minerals – Director Dealing
Tertiary Minerals (TYM), the AIM traded company building a strategic position in the fluorspar sector, announces that, following Mr Richard Clemmey’s purchase of ordinary shares in the Company on 30 December 2015 as previously announced, the Company was notified on 26 January 2016 that Mr Clemmey had acquired a further 131,533 ordinary shares of 1p […]
Advanced Oncotherapy – Additional Director Dealing
Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share. The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, […]
Advanced Oncotherapy – Additional Director Dealing
Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 1,000,000 ordinary shares of 1 penny each in the Company at 5.75 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 123,768,510 Ordinary Shares representing 8.73% of the issued […]
Advanced Oncotherapy – Director Dealing
Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 750,000 ordinary shares of 1 penny each in the Company at 5.5 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 122,768,510 Ordinary Shares representing 8.66% of the […]